Ken Marek, MD

President and Senior Scientist
Institute of Neurodegenerative Disorders

Kenneth Marek is President and Senior Scientist at the Institute for Neurodegenerative Disorders and Clinical Professor of Neurology at Yale University. He was graduated from Princeton University (AB, biochemistry) and received his medical degree from Yale University. Dr. Marek was trained in internal medicine and neurology at the Johns Hopkins School of Medicine and is board certified in both of these specialties. He received further training as a post-doctoral fellow in neurochemistry at the Institute of Neurology, Queens Square, London. He has been a faculty member in the departments of neurology at Johns Hopkins University and Yale University. Dr. Marek has been the recipient of numerous grants and awards including those from the National Institutes of Health, Department of Defense, Disease Foundation, and National Parkinson’s Foundation. He serves on the scientific advisory board of the Michael J Fox Foundation. He was a co-founder and continues to lead the AMADEUS consortium, an international SPECT imaging consortium for multi-center neuroimaging in clinical studies. He has served on the executive committee of the Parkinson’s Study Group and in leadership roles in the Huntington Study group. He also was a co-founder of Molecular NeuroImaging, LLC, a company providing clinical neuroimaging research services. Dr. Marek’s major research interests include the identification of biomarkers for early detection, assessment of disease progression and development of new treatments for Parkinson’s disease and Alzheimer’s disease and related neurodegenerative disorders. His specific interest has been in vivo neuroreceptor imaging. He has authored numerous neurology and neuroscience publications on these topics. Dr. Marek has and continues to be the principal investigator of several ongoing multi-center international studies investigating the use of imaging to assess the onset, progression, and effect of treatment in Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative diseases.